Nanotechnology-Enhanced Vaccines: New inulin bioconjugates to defeat global pandemic threats

纳米技术增强疫苗：新型菊粉生物共轭物可战胜全球大流行威胁

• 批准号: LP0882596
• 负责人: Dr Milena Ginic-Markovic
• 金额: $ 9.37万
• 依托单位: Flinders University
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-11-30 至 2012-02-29
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0882596
• 关键词: Nanotechnology; Enhanced; Vaccines; New; inulin

Inulin-based adjuvants have the potential to revolutionise the vaccine arena; man's critical first line of defence against infectious disease. Any breakthrough in developing completely safe new adjuvants, will therefore be of major global significance, and will play a vital role in the maintenance of global health for decades. New and completely safe vaccine adjuvants are a vital step in the development of improved vaccine technology in the 21st century. This project addresses two National Research Priorities, Namely Promoting and Maintaining Good Health and Safeguarding Australia. On commercialization, this will then be an important Australian contribution towards protecting the nation against any future pandemic outbreaks.

以菊粉为基础的佐剂有可能彻底改变疫苗领域；人类抵御传染病的关键第一道防线。因此，在开发完全安全的新型佐剂方面取得的任何突破都将具有重大的全球意义，并将在未来几十年维护全球健康方面发挥至关重要的作用。新型和完全安全的疫苗佐剂是21世纪改进疫苗技术发展的重要一步。该项目涉及两个国家研究优先事项，即促进和保持良好健康和保护澳大利亚。在商业化方面，这将是澳大利亚对保护国家免受未来任何大流行病爆发的重要贡献。